Stocklytics Platform
Asset logo for symbol VTGN
VistaGen Therapeutics
VTGN65
$3.000.00%$0.00
Penny Stock
Asset logo for symbol VTGN
VTGN65

$3.00

0.00%

Performance History

Chart placeholder
no data available for key stats

There's no data available for key stats

no data available for ratios/profitability stats

There's no data available for ratios/profitability stats

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

About VistaGen Therapeutics (VTGN)

VistaGen Therapeutics Inc (VTGN) is a biopharmaceutical company focused on developing innovative treatments to address unmet medical needs in the field of mental health. With a strong emphasis on utilizing cutting-edge stem cell technology, VistaGen is at the forefront of revolutionizing the way mental health disorders are diagnosed, treated, and managed. The company's vision is to provide patients with safer, more effective, and personalized therapies that can significantly improve their quality of life.
As of the latest market data, VistaGen Therapeutics Inc has a market capitalization of $XXX million. The company's stock, VTGN, has demonstrated a volatile trading history over the past year, with a 52-week range of $X.XX to $X.XX. The day range for VTGN currently stands at $X.XX to $X.XX. During recent trading sessions, the stock has seen notable trading volume, indicating increased investor interest.
Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Shawn K. Singh J.D.
Headquarters
South San Francisco
Employees
32
Exchange
NASDAQ
add VistaGen Therapeutics  to watchlist

Keep an eye on VistaGen Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is VistaGen Therapeutics 's (VTGN) price per share?

The current price per share for VistaGen Therapeutics (VTGN) is $3. The stock has seen a price change of $0 recently, indicating a 0% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for VistaGen Therapeutics (VTGN)?

For VistaGen Therapeutics (VTGN), the 52-week high is $5.86, which is 95.33% from the current price. The 52-week low is $2.45, the current price is 22.45% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is VistaGen Therapeutics (VTGN) a growth stock?

VistaGen Therapeutics (VTGN) has shown an average price growth of 0.41% over the past three years. It has received a score of 14 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying VistaGen Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is VistaGen Therapeutics (VTGN) stock price performance year to date (YTD)?

As of the latest data, VistaGen Therapeutics (VTGN) has a year-to-date price change of -41.75%. Over the past month, the stock has experienced a price change of -13.54%. Over the last three months, the change has been -6.83%. Over the past six months, the figure is -27.71%. Looking at a longer horizon, the five-year price change stands at -91.6%.
help

Is VistaGen Therapeutics (VTGN) a profitable company?

VistaGen Therapeutics (VTGN) has a net income of -$29.36M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 46.62% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -14.44K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $1.06M, although specific revenue growth data is currently not available. The gross profit is $496K. Operating income is noted at -$33.02M. Furthermore, the EBITDA is -$38.02M.
help

What is the market capitalization of VistaGen Therapeutics (VTGN)?

VistaGen Therapeutics (VTGN) has a market capitalization of $81.03M. The average daily trading volume is 131.37K, indicating the stock's liquidity and investor engagement.

News

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level

Stocklytics Platform

© 2024 Stocklytics.com All rights reserved.

Stocklytics.com is not a financial advisor, and all data and information provided on this website are for informational purposes only. The content on Stocklytics.com is not intended to be a substitute for professional financial advice. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions. Stocklytics.com makes no representations or warranties regarding the accuracy, completeness, or suitability of any information provided and is not liable for any errors or omissions, or for any losses incurred as a result of reliance on the information provided on this website.

Stocklytics Discord public channelStocklytics X Social Media